Levetiracetam: A different approach to the pharmacotherapy of epilepsy

Annals of Pharmacotherapy

Volumn 36, Issue 2, 2002, Pages 296-304

  Welty, Timothy E ^a,b   Gidal, Barry E ^c   Ficker, David M ^d   Privitera, Michael D ^d  

^a SAMFORD UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Epilepsy; Levetiracetam; Seizures

Indexed keywords

ETIRACETAM; PLACEBO;

ADOLESCENT; ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; EPILEPSY; EPILEPTOGENESIS; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDLINE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANIMALS; ANTICONVULSANTS; EPILEPSY; HUMANS; MEDLINE; PIRACETAM; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0036159535     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A032     Document Type: Article

References (31)

1. Levetiracetam
2. Pharmacokinetic profile of levetiracetam: Toward ideal characteristics
3. Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia
4. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
5. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (UCB L059) in the kindling model of temporal lobe epilepsy
6. Levetiracetam: Novel modulation of ionotrophic inhibitory receptors
7. Levetiracetam: No relevant effect on ionotrophic excitatory glutamate receptors
8. The novel antiepileptic drug levetiracetam (UCB L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata
9. Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain
10. Inhibition by levetiracetam of a non-GABA(A) receptor-associated epileptiform effect of bicuculline in rat hippocampus
11. 2+ current in CA1 pyramidal neurons of rat hippocampal slices
12. The novel antiepileptic drug levetiracetam (UCB L059) appears to act via a specific binding site in CNS membranes
13. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (UCB L059) in the rat
14. Microdialysis study of levetiracetam in rat frontal cortex and hippocampus
15. Absence of pharmacokinetic drug interactions of levetiracetam with phenytoin in patients with epilepsy determined by new technique
16. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent
17. Efficacy and tolerability study of UCB L059 in patients with refractory epilepsy
18. Levetiracetam does not interact with other antiepileptic drugs
19. Valproate does not alter levetiracetam pharmacokinetics
20. Lack of effect of repeated administration of levetiracetam on the pharmacokinetic and pharmacodynamic profiles of warfarin
21. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers
22. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures
23. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy
24. Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial
25. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy
26. Efficacy and adverse effects of gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, zonisamide and vagal nerve stimulator
27. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy
28. Effect of levetiracetam on epilepsy-related quality of life